1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,730 | 1,820 | 12:14 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| Mo | HAOHAI BIOTEC 9M Net Profit Falls 46.53% YoY to RMB163 million | 2 | AASTOCKS | ||
| 23.10. | HAOHAI BIOTEC (06826): 2026 THIRD QUARTERLY REPORT | 1 | HKEx | ||
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 12.10. | HAOHAI BIOTEC (06826): DATE OF BOARD MEETING | 1 | HKEx | ||
| 18.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 09.09. | HAOHAI BIOTEC (06826): (REVISED) NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 08.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 07.09. | HAOHAI BIOTEC (06826): INTERIM REPORT 2026 | 1 | HKEx | ||
| 04.09. | Dividendenbekanntmachungen (04.09.2026) | 16.110 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAON INC US0003602069 0,1 USD 0,086 EUR ACUSHNET HOLDINGS CORP US0050981085 0,255 USD 0,2193 EUR AIA GROUP LTD HK0000069689 0... ► Artikel lesen | |
| 01.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 24.08. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 21.08. | Shanghai Haohai Biological Technology Co., Ltd Profit Retreats In H1 | 2 | RTTNews | ||
| 21.08. | HAOHAI BIOTEC (06826): CHANGE OF AUTHORIZED REPRESENTATIVE | - | HKEx | ||
| 21.08. | HAOHAI BIOTEC (06826): DISTRIBUTION AND PAYMENT OF 2026 INTERIM DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS | 1 | HKEx | ||
| 21.08. | HAOHAI BIOTEC (06826): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2026 | - | HKEx | ||
| 11.08. | HAOHAI BIOTEC (06826): DATE OF BOARD MEETING | 5 | HKEx | ||
| 20.07. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 22.06. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 04.06. | Dividendenbekanntmachungen (04.06.2026) | 15.854 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| 29.05. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | - | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,492 | -2,47 % | Valneva nach Zulassungsentzug in Großbritannien: Diese Marke entscheidet jetzt | ||
| AMGEN | 421,55 | +0,08 % | Antikörper: Amgen zieht Tepezza zurück | ||
| STRYKER | 248,00 | +0,49 % | Ihre wichtigsten Termine: Spannende Zahlen von: Amazon, Starbucks, Mastercard, Eli Lilly und Caterpillar | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: FR0000120073,US0231351067... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 765,00 | +3,90 % | Regeneron Pharmaceuticals Inc Reports Increase In Q3 Income | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) reported earnings for its third quarter that Increases, from last yearThe company's earnings totaled $1.949 billion, or $18.45 per... ► Artikel lesen | |
| CSL | 124,68 | +0,82 % | CSL LIMITED: Update - Notification of buy-back - CSL | ||
| BEONE MEDICINES LTD ADR | 334,00 | 0,00 % | BeOne Medicines Ltd.: BeOne präsentiert auf der ESMO 2026 überzeugende Daten zu schwer zu behandelndem Leber- und Lungenkrebs | Potenziell erster bispezifischer GPC3 x 4-1BB Antikörper seiner Klasse erzielt bei der Phase-3-Dosis eine bestätigte Ansprechrate von 36 und zeigt ein günstiges Sicherheitsprofil bei stark vorbehandeltem... ► Artikel lesen | |
| CANSINO BIOLOGICS | 3,000 | +1,35 % | CanSino Biologics Inc: CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth | HONG KONG, Oct 27, 2026 - (ACN Newswire) - On October 27, 2026, CanSino Biologics Inc. (HKEX: 06185; SSE: 688185) released its third-quarter financial report for 2026. For the nine months ended September... ► Artikel lesen | |
| BIOMERIEUX | 91,30 | 0,00 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| SINO BIOPHARM | 0,543 | -0,89 % | SBP GROUP Two Hepatitis B New Drugs Included in Breakthrough Therapy Designation Program | ||
| ZAI LAB LTD ADR | 20,400 | +2,00 % | Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer | At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,520 | 0,00 % | CStone Pharmaceuticals: CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity | CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
CS2009, an Innovative PD-1/VEGF/CTLA-4... ► Artikel lesen | |
| CASI PHARMACEUTICALS | 0,214 | -4,13 % | CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results | SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody... ► Artikel lesen | |
| 3SBIO | 1,614 | -0,73 % | 3SBio Inc.: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth | SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,156 | 0,00 % | G Sachs Raises INNOVENT BIO TP to HKD122.28 as 3Q Product Sales Meet Expectations | ||
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,730 Euro und damit 0,00 % im Plus. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.